MedTrace Logo

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

NCT00749892 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-09-10

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Recurrent Bladder Urothelial Carcinoma
  • Recurrent Renal Pelvis Urothelial Carcinoma
  • Recurrent Ureter Urothelial Carcinoma
  • Recurrent Urethral Urothelial Carcinoma
  • Stage 0a Bladder Cancer AJCC v8
  • Stage 0a Renal Pelvis Cancer AJCC v8
  • Stage 0a Ureter Cancer AJCC v8
  • Stage 0a Urethral Cancer AJCC v8
  • Stage 0is Bladder Cancer AJCC v8
  • Stage 0is Renal Pelvis Cancer AJCC v8
  • Stage 0is Ureter Cancer AJCC v8
  • Stage 0is Urethral Cancer AJCC v8
  • Stage II Bladder Cancer AJCC v8
  • Stage II Renal Pelvis Cancer AJCC v8
  • Stage II Ureter Cancer AJCC v8
  • Stage II Urethral Cancer AJCC v8
  • Stage III Renal Pelvis Cancer AJCC v8
  • Stage III Ureter Cancer AJCC v8
  • Stage III Urethral Cancer AJCC v8
  • Stage IIIA Bladder Cancer AJCC v8

Interventions

DRUG

Erlotinib Hydrochloride

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Arlene Siefker-Radtke · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-10
Primary Completion
2019-06-30
Completion
2019-11-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749892 on ClinicalTrials.gov